New Antibody Treatment Effective Against Omicron Variant

About a week ago, there was a significant dustup over the government halting several monoclonal antibody treatment disbursements.

According to Governor Ron DeSantis, the government claimed the treatments were not effective against Omicron, even though the claim was being backed by one limited study with no peer review.

DeSantis went on to say that Florida had been using those treatments with success.

That may all be mute now that a new therapy has been discovered that is touted as being effective against the new COVID variant.

New Treatment

The FDA has already approved the new treatment.

The drug is called bebtelovimab and it is to be used for “mild to moderate COVID-19 in adults and pediatric patients.”

This would include individuals who have tested positive but are at high risk.

Patrizia Cavazzoni, the director of the FDA’s Center for Drug Evaluation and Research, stated that this is “an important step in meeting the need for more tools to treat patients as new variants of the virus continue to emerge.”

The FDA added, “The new treatment is not a substitute for vaccination in individuals for whom a vaccination and a booster dose are recommended.”

Even though the treatment has been approved, I have seen considering pushback on this on social media.

Again, the biggest concern is that the FDA is approving or disapproving something based on very limited studies.

Other treatments out there have been through far more scrutiny and proven to be effective, only they were touted during the Trump administration, and the FDA does not seem inclined to approve them for use against COVID.

Source: Just the News


Sign Up for Daily Newsletter

By submitting this form, you are consenting to receive breaking news updates emails from: Breaking News Digest, LLC, 299 Monroe Ave., Suite 2406, Roanoke, TX, 76262, US, https://www.Breaking News You can revoke your consent to receive emails at any time by using the link, found at the bottom of every email. 




Twitter feed is not available at the moment.